A literature review found COPD and chronic kidney disease (CKD) frequently co-occur and that COPD can adversely affect renal function via shared risk factors and lung–kidney mechanisms—raising risks for cardiovascular events, hospitalizations, and mortality. The review highlights management implications for dosing, electrolytes, and acid–base balance, and supports routine screening with both creatinine and cystatin C.

Why It Matters To Your Practice

• Coexisting COPD and CKD can compound prognosis, with higher risk for cardiovascular events, hospitalizations, and death (including in patients with heart disease).

• Renal impairment can be under-recognized in COPD if you rely on creatinine alone; adding cystatin C may improve detection and risk stratification.

• CKD changes the “rules” during acute exacerbations: fluid strategy, oxygenation/ventilation decisions, and medication choices can have bigger downstream renal consequences.

Clinical Benefits

• Earlier identification of CKD in COPD enables safer prescribing (renal dosing, avoidance of nephrotoxins) and more proactive monitoring.

• Routine assessment of electrolytes and acid–base status can help prevent complications that worsen dyspnea, fatigue, arrhythmia risk, and exacerbation recovery.

• Multidisciplinary care (pulmonary + nephrology + primary care/pharmacy) can streamline medication reconciliation and reduce preventable admissions.

Managing Risks

• Screen deliberately: check eGFR and urine albumin when appropriate, and consider cystatin C to clarify kidney function—especially in older adults, low muscle mass, or borderline creatinine.

• Plan for renal-sensitive prescribing: adjust doses to kidney function, monitor potassium/bicarbonate, and reassess meds during exacerbations when dehydration, hypoxemia, or infection can accelerate kidney injury.

• Watch for compounding cardio-renal-pulmonary stress: COPD + CKD increases vulnerability to volume shifts, acid–base disturbances, and cardiovascular events—tighten follow-up after ED visits or steroid/antibiotic starts.

The Bottom Line

• COPD and CKD are a high-risk pairing, and COPD may contribute to kidney decline—so build kidney screening and renal-aware medication management into routine COPD care.

• Using both creatinine and cystatin C, plus closer electrolyte/acid–base monitoring during exacerbations, can improve safety and outcomes.